Thursday, December 28, 2023 10:19:09 AM
You understand I'm not saying Anavex initially lied intentionally, which would have been illegal, unethical, and stupid. If it did happen, I believe it was primarily the result of bad fortune. Anavex got the P2b/3 results a day before CTAD 2022, due to its CRO's problems. Additionally, IIRC, Anavex has said it hadn't run its own statistics for the P2b/3 at that point; the statistical analysis was initially handled by the CRO. I believe Anavex felt a great deal of pressure to present the trial results in its scheduled time slot at CTAD. MacFarlane has said he didn't get his slides until an hour before he presented them. The Anavex office (virtual or not) must have been very chaotic in the day leading up to the presentation.
December 1, the day of the all-endpoints-met PR and CTAD presentation, was a Thursday. Friday the share price shoots way up on the news on huge volume, and then starts sliding back down. (I personally bought a lot of shares in the pre-market and remain well underwater.) I don't know when they figure out there's a problem, but Missling's performance on the December 5 conference call was somewhere on the spectrum between unimpressive and abysmal. I think he didn't get much sleep that weekend.
Please agree, even hypothetically, there's a chance that my facts above are generally right and that Anavex discovered at some point after December 1 that they hadn't actually met all endpoints. What do you think Anavex should have done about the unintentional misinformation (ADL endpoint met) at that point? I believe that had it announced the error, it would have finished the company in a sea of lawsuits. Let's say for the hypothetical that Odds Ratio was the second-listed statistical test in the hierarchy, and accept my understanding that meeting a not-first-listed test is not really meeting an endpoint.
December 1, the day of the all-endpoints-met PR and CTAD presentation, was a Thursday. Friday the share price shoots way up on the news on huge volume, and then starts sliding back down. (I personally bought a lot of shares in the pre-market and remain well underwater.) I don't know when they figure out there's a problem, but Missling's performance on the December 5 conference call was somewhere on the spectrum between unimpressive and abysmal. I think he didn't get much sleep that weekend.
Please agree, even hypothetically, there's a chance that my facts above are generally right and that Anavex discovered at some point after December 1 that they hadn't actually met all endpoints. What do you think Anavex should have done about the unintentional misinformation (ADL endpoint met) at that point? I believe that had it announced the error, it would have finished the company in a sea of lawsuits. Let's say for the hypothetical that Odds Ratio was the second-listed statistical test in the hierarchy, and accept my understanding that meeting a not-first-listed test is not really meeting an endpoint.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM

